KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accounts Payables (2018 - 2025)

Castle Biosciences' Accounts Payables history spans 7 years, with the latest figure at $18.7 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 171.13% year-over-year to $18.7 million; the TTM value through Dec 2025 reached $18.7 million, up 171.13%, while the annual FY2025 figure was $18.7 million, 171.13% up from the prior year.
  • Accounts Payables for Q4 2025 was $18.7 million at Castle Biosciences, up from $12.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.7 million in Q4 2025 and bottomed at $1.4 million in Q2 2021.
  • The 5-year median for Accounts Payables is $6.9 million (2023), against an average of $7.3 million.
  • The largest annual shift saw Accounts Payables tumbled 45.17% in 2021 before it surged 200.57% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $2.5 million in 2021, then soared by 85.82% to $4.7 million in 2022, then skyrocketed by 117.04% to $10.3 million in 2023, then crashed by 32.79% to $6.9 million in 2024, then surged by 171.13% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Accounts Payables are $18.7 million (Q4 2025), $12.2 million (Q3 2025), and $13.2 million (Q2 2025).